<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pulmonary Medicine - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcpulmmed/</link>
		<description>The latest articles from BMC Pulmonary Medicine (ISSN 1471-2466) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/21"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/20"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/19"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/18"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/17"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/16"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/15"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/14"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/12"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/11"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/21">
            
            <title>Autoadjusting-CPAP effect on serum Leptin concentrations in Obstructive Sleep Apnoea patients</title>
			<description>Background:
Leptin is an hormone that regulates body weight.  Studies have shown increasing leptin concentrations according to body mass index (BMI) and intermittent hypoxia.
Our aim is to evaluate the basal leptin levels in OSA patients and its possible relation to OSA severity, independently of confounders and investigate the Autoadjusting-CPAP effect on leptin values.
Methods:
In ninety eight male patients with moderate to severe OSA leptin serum levels were evaluated before therapy, 9 days and 6 months after therapy.
Results:
In this group mean age was 55.3 years, mean BMI was 33.2 Kg/m2 and mean Apnoea- Hypopnea Index (AHI) was 51.7/h. Mean basal serum leptin value was 12.1 ug/L. Univariate analysis showed a significant correlation between serum leptin values and BMI (R= 0.68; p&lt;0.001), waist-hip ratio (R= 0.283; p=0.004) and AHI (R= 0.198; p=0.048); in stepwise multiple regression analysis only BMI (p&lt;0.001) was a predictor of serum leptin values.
One week after therapy, mean leptin serum level decreased to 11.0 ug/L and 6 months after it was 11.4 ug/L. (p=0.56 and p=0.387, respectively)
Conclusions:
Baseline leptin serum levels positively correlate with BMI, fat distribution and OSA severity.
BMI is the only predictor of basal leptin levels.
Treatment with Autoadjusting-CPAP has a small effect on leptin levels.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/21</link>
			
			 	<dc:creator>Marta Drummond, Joao C Winck, Joao T Guimaraes, Ana C Santos, Joao Almeida and Jose A Marques</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:21</dc:source>
			<dc:date>2008-10-01</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-21</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/20">
            
            <title>Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension</title>
			<description>Background:
Endothelin-1 (ET-1) and Nitric Oxide (NO) are crucial mediators for establishing pulmonary artery hypertension (PAH). We tested the hypothesis that their imbalance might also occur in COPD patients with PAH.
Methods:
The aims of the study were to measure exhaled breath condensate (EBC) and circulating levels of ET-1, as well as exhaled NO (FENO) levels by, respectively, a specific enzyme immunoassay kit, and by chemiluminescence analysis in 3 groups of subjects: COPD with PAH (12), COPD only (36), and healthy individuals (15). In order to evaluate pulmonary-artery systolic pressure (PaPs), all COPD patients underwent Echo-Doppler assessment.
Results:
Significantly increased exhaled and circulating levels of ET-1 were found in COPD with PAH compared to both COPD (p &lt; 0.0001) only, and healthy controls (p &lt; 0.0001). In COPD with PAH, linear regression analysis showed good correlation between ET-1 in EBC and PaPs (r = 0.621; p = 0.031), and between arterial levels of ET-1 and PaPs (r = 0.648; p = 0.022), while arterial levels of ET-1 inversely correlated with FEV1%, (r = -0.59, p = 0.043), and PaPs negatively correlated to PaO2 (r = -0.618; p = 0.032). Significantly reduced levels of FENO were found in COPD associated with PAH, compared to COPD only (22.92 &#177; 11.38 vs.35.07 &#177; 17.53 ppb; p = 0.03). Thus, we observed an imbalanced output in the breath between ET-1 and NO, as expression of pulmonary endothelium and epithelium impairment, in COPD with PAH compared to COPD only. Whether this imbalance is an early cause or result of PAH due to COPD is still unknown and deserves further investigations.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/20</link>
			
			 	<dc:creator>Pierluigi Carratu, Cristina Scoditti, Mauro Maniscalco, Teresa Maria Seccia, Giuseppe Di Gioia, Felice Gadaleta, Rosa Angela Cardone, Silvano Dragonieri, Paola Pierucci, Antonio Spanevello and Onofrio Resta</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:20</dc:source>
			<dc:date>2008-09-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-20</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/19">
            
            <title>Early intestinal Bacteroides fragilis colonisation and development of asthma</title>
			<description>Background:
The 'hygiene hypothesis' suggests that early exposure to microbes can be protective against atopic disease. The intestinal microbial flora could operate as an important postnatal regulator of the Th1/Th2 balance. The aim of the study was to investigate the association between early intestinal colonisation and the development of asthma in the first 3 years of life.
Methods:
In a prospective birth cohort, 117 children were classified according to the Asthma Predictive Index. A positive index included wheezing during the first three years of life combined with eczema in the child in the first years of life or with a parental history of asthma. A faecal sample was taken at the age of 3 weeks and cultured on selective media.
Results:
Asthma Predictive Index was positive in 26/117 (22%) of the children. The prevalence of colonisation with Bacteroides fragilis was higher at 3 weeks in index+ compared to index- children (64% vs. 34% p &lt; 0,05). Bacteroides fragilis and Total Anaerobes counts at 3 weeks were significantly higher in children with a positive index as compared with those without. After adjusting for confounders a positive association was found between Bacteroides fragilis colonisation and Asthma Predictive Index (odds ratio: 4,4; confidence interval: 1,7 &#8211; 11,8).
Conclusion:
Bacteroides fragilis colonisation at age 3 weeks is an early indicator of possible asthma later in life. This study could provide the means for more accurate targeting of treatment and prevention and thus more effective and better controlled modulation of the microbial milieu.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/19</link>
			
			 	<dc:creator>Carl Vael, Vera Nelen, Stijn L Verhulst, Herman Goossens and Kristine N Desager</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:19</dc:source>
			<dc:date>2008-09-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-19</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>19</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/18">
            
            <title>Post tracheostomy and post intubation tracheal stenosis: Report of 31 cases and review of the literature</title>
			<description>Background:
Severe post tracheostomy (PT) and post intubation (PI) tracheal stenosis is an uncommon clinical entity that often requires interventional bronchoscopy before surgery is considered. We present our experience with severe PI and PT stenosis in regards to patient characteristics, possible risk factors, and therapy.
Methods:
We conducted a retrospective chart review of 31 patients with PI and PT stenosis treated at Lahey Clinic over the past 8 years. Demographic characteristics, body mass index, co-morbidities, stenosis type and site, procedures performed and local treatments applied were recorded.
Results:
The most common profile of a patient with tracheal stenosis in our series was a female (75%), obese (66%) patient with a history of diabetes mellitus (35.4%), hypertension (51.6%), and cardiovascular disease (45.1%), who was a current smoker (38.7%). Eleven patients (PI group) had only oro-tracheal intubation (5.2 days of intubation) and developed web-like stenosis at the cuff site. Twenty patients (PT group) had undergone tracheostomy (54.5 days of intubation) and in 17 (85%) of them the stenosis appeared around the tracheal stoma. There was an average of 2.4 procedures performed per patient. Rigid bronchoscopy with Nd:YAG laser and dilatation (mechanical or balloon) were the preferred methods used. Only 1(3.2%) patient was sent to surgery for re-stenosis after multiple interventional bronchoscopy treatments.
Conclusion:
We have identified putative risk factors for the development of PI and PT stenosis. Differences in lesions characteristics and stenosis site were noted in our two patient groups. All patients underwent interventional bronchoscopy procedures as the first-line, and frequently the only treatment approach.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/18</link>
			
			 	<dc:creator>Nikolaos Zias, Alexandra Chroneou, Maher K Tabba, Anne V Gonzalez, Anthony W Gray, Carla R Lamb, David R Riker and John F Beamis</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:18</dc:source>
			<dc:date>2008-09-21</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-18</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/17">
            
            <title>Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice</title>
			<description>Background:
We reported that roflumilast, a phosphodiesterase 4 inhibitor, given orally at 5 mg/kg to mice prevented the development of emphysema in a chronic model of cigarette smoke exposure, while at 1 mg/kg was ineffective. Here we investigated the effects of roflumilast on the volume density (VV) of the inflammatory cells present in the lungs after chronic cigarette smoke exposure.
Methods:
Slides were obtained from blocks of the previous study and VV was assessed immunohistochemically and by point counting using a grid with 48 points, a 20&#215; objective and a computer screen for a final magnification of 580&#215;. Neutrophils were marked with myeloperoxidase antibody, macrophages with Mac-3, dendritic cells with fascin, B-lymphocytes with B220, CD4+ T-cells with CD4+ antibody, and CD8+T-cells with CD8-&#945;. The significance of the differences was calculated using one-way analysis of variance.
Results:
Chronic smoke exposure increased neutrophil VV by 97%, macrophage by 107%, dendritic cell by 217%, B-lymphocyte by 436%, CD4+ by 524%, and CD8+ by 417%. The higher dose of roflumilast prevented the increase in neutrophil VV by 78%, macrophage by 82%, dendritic cell by 48%, B-lymphocyte by 100%, CD4+ by 98% and CD8+ VV by 88%. The lower dose of roflumilast did not prevent the increase in neutrophil, macrophage and B-cell VV but prevented dendritic cells by 42%, CD4+ by 55%, and CD8+ by 91%.
Conclusion:
These results indicate (i) chronic exposure to cigarette smoke in mice results in a significant recruitment into the lung of inflammatory cells of both the innate and adaptive immune system; (ii) roflumilast at the higher dose exerts a protective effect against the recruitment of all these cells and at the lower dose against the recruitment of dendritic cells and T-lymphocytes; (iii) these findings underline the role of innate immunity in the development of pulmonary emphysema and (iiii) support previous results indicating that the inflammatory cells of the adaptive immune system do not play a central role in the development of cigarette smoke induced emphysema in mice.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/17</link>
			
			 	<dc:creator>Piero A Martorana, Benedetta Lunghi, Monica Lucattelli, Giovanna De Cunto, Rolf Beume and Giuseppe Lungarella</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:17</dc:source>
			<dc:date>2008-08-28</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-17</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/16">
            
            <title>Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study</title>
			<description>Background:
Community-acquired (CAP) and nosocomial pneumonias contribute substantially to morbidity and hospital resource utilization. Hyponatremia, occurring in >1/4 of patients with CAP, is associated with greater disease severity and worsened outcomes.
Methods:
To explore how hyponatremia is associated with outcomes in hospitalized patients with pneumonia, we analyzed a large administrative database with laboratory component from January 2004 to December 2005. Hyponatremia was defined as at least two [Na+] &lt; 135 mEq/L within 24 hours of admission value.
Results:
Of 7,965 patients with pneumonia, 649 (8.1%) with hyponatremia were older (72.4 &#177; 15.7 vs. 68.0 &#177; 22.0, p &lt; 0.01), had a higher mean Deyo-Charlson Comorbidity Index Score (1.7 &#177; 1.7 vs. 1.6 &#177; 1.6, p = 0.02), and higher rates of ICU (10.0% vs. 6.3%, p &lt; 0.001) and MV (3.9% vs. 2.3%, p = 0.01) in the first 48 hours of hospitalization than patients with normal sodium. Hyponatremia was associated with an increased ICU (6.3 &#177; 5.6 vs. 5.3 &#177; 5.1 days, p = 0.07) and hospital lengths of stay (LOS, 7.6 &#177; 5.3 vs. 7.0 &#177; 5.2 days, p &lt; 0.001) and a trend toward increased hospital mortality (5.4% vs. 4.0%, p = 0.1). After adjusting for confounders, hyponatremia was associated with an increased risk of ICU (OR 1.58, 95% CI 1.20&#8211;2.08), MV (OR 1.75 95% CI 1.13&#8211;2.69), and hospital death (OR 1.3, 95% CI 0.90&#8211;1.87) and with increases of 0.8 day to ICU and 0.3 day to hospital LOS, and over $1,300 to total hospital costs.
Conclusion:
Hyponatremia is common among hospitalized patients with pneumonia and is associated with worsened clinical and economic outcomes. Studies in this large population are needed to explore whether prompt correction of [Na+] may impact these outcomes.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/16</link>
			
			 	<dc:creator>Marya D Zilberberg, Alex Exuzides, James Spalding, Aimee Foreman, Alison Graves Jones, Chris Colby and Andrew F Shorr</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:16</dc:source>
			<dc:date>2008-08-18</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-16</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/15">
            
            <title>Angiotensin-converting enzyme genotype and late respiratory complications of mustard gas exposure</title>
			<description>Background:
Exposure to mustard gas frequently results in long-term respiratory complications. However the factors which drive the development and progression of these complications remain unclear. The Renin Angiotensin System (RAS) has been implicated in lung inflammatory and fibrotic responses. Genetic variation within the gene coding for the Angiotensin Converting Enzyme (ACE), specifically the Insertion/Deletion polymorphism (I/D), is associated with variable levels of ACE and with the severity of several acute and chronic respiratory diseases. We hypothesized that the ACE genotype might influence the severity of late respiratory complications of mustard gas exposure.
Methods:
208 Kurdish patients who had suffered high exposure to mustard gas, as defined by cutaneous lesions at initial assessment, in Sardasht, Iran on June 29 1987, underwent clinical examination, spirometric evaluation and ACE Insertion/Deletion genotyping in September 2005.
Results:
ACE genotype was determined in 207 subjects. As a continuous variable, FEV1 % predicted tended to be higher in association with the D allele 68.03 &#177; 20.5%, 69.4 &#177; 21.4% and 74.8 &#177; 20.1% for II, ID and DD genotypes respectively. Median FEV1 % predicted was 73 and this was taken as a cut off between groups defined as having better or worse lung function. The ACE DD genotype was overrepresented in the better spirometry group (Chi2 4.9 p = 0.03). Increasing age at the time of exposure was associated with reduced FEV1 %predicted (p = 0.001), whereas gender was not (p = 0.43).
Conclusion:
The ACE D allele is associated with higher FEV1 % predicted when assessed 18 years after high exposure to mustard gas.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/15</link>
			
			 	<dc:creator>Ali Reza Hosseini-khalili, Julian Thompson, Anthony Kehoe, Nicholas S Hopkinson, A Khoshbaten, Mohammad Reza Soroush, Steve E Humphries, Hugh Montgomery and Mostafa Ghanei</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:15</dc:source>
			<dc:date>2008-08-14</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-15</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/14">
            
            <title>Discriminative and predictive properties of disease-specific and generic health status indexes in elderly COPD patients</title>
			<description>Background:
The association between bronchial obstruction severity and mortality in Chronic Obstructive Pulmonary Disease (COPD) is well established, but it is unknown whether disease-specific health status measures and multidimensional assessment (MDA) have comparable prognostic value.
Methods:
We analyzed data coming from the Salute Respiratoria nell'Anziano (Respiratory Health in the Elderly &#8211; SaRA) study, enrolling elderly people attending outpatient clinics for respiratory and non-respiratory problems. From this population we selected 449 patients with bronchial obstruction (77.3% men, mean age 73.1). We classified patients' health status using tertiles of the Saint George Respiratory Questionnaire (SGRQ) and a MDA including functional (the 6' walking test, WT), cognitive (Mini-Mental State Examination, MMSE) and affective status (Geriatric Depression Scale, GDS). The agreement of the classification methods was calculated using the kappa statistic, and survival associated with group membership was evaluated using survival analysis.
Results:
Pulmonary function, expressed by the FEV1, worsened with increasing SGRQ or MDA scores. Cognitive function was not associated with the SGRQ, while physical performance and mood status were impaired only in the highest tertile of SGRQ. A poor agreement was found between the two classification systems tested (k = 0.194). Compared to people in the first tertile of SGRQ score, those in the second tertile had a sex-adjusted HR of 1.22 (0.75 &#8211; 1.98) and those in the third tertile of 2.90 (1.92 &#8211; 4.40). The corresponding figures of the MDA were 1.49 (95% CI 1.02 &#8211; 2.18) and 2.01 (95% CI: 1.31 &#8211; 3.08). After adjustment for severity of obstruction, only a SGRQ in the upper tertile was associated with mortality (HR: 1.86; 95% CI: 1.14 &#8211; 3.02).
Conclusion:
In elderly outpatients with mild-moderate COPD, a disease-specific health status index seems to be a better predictor of death compared to a MDA.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/14</link>
			
			 	<dc:creator>Maria E Conte, Claudio Pedone, Francesco Forastiere, Vincenzo Bellia and Raffaele Antonelli-Incalzi</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:14</dc:source>
			<dc:date>2008-08-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-14</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/13">
            
            <title>Human eosinophil adhesion and degranulation stimulated with eotaxin and RANTES in vitro: Lack of interaction with nitric oxide</title>
			<description>Background:
Airway eosinophilia is considered a central event in the pathogenesis of asthma. The toxic components of eosinophils are thought to be important in inducing bronchial mucosal injury and dysfunction. Previous studies have suggested an interaction between nitric oxide (NO) and chemokines in modulating eosinophil functions, but this is still conflicting. In the present study, we have carried out functional assays (adhesion and degranulation) and flow cytometry analysis of adhesion molecules (VLA-4 and Mac-1 expression) to evaluate the interactions between NO and CC-chemokines (eotaxin and RANTES) in human eosinophils.
Methods:
Eosinophils were purified using a percoll gradient followed by immunomagnetic cell separator. Cell adhesion and degranulation were evaluated by measuring eosinophil peroxidase (EPO) activity, whereas expression of Mac-1 and VLA-4 was detected using flow cytometry.
Results:
At 4 h incubation, both eotaxin (100 ng/ml) and RANTES (1000 ng/ml) increased by 133% and 131% eosinophil adhesion, respectively. L-NAME alone (but not D-NAME) also increased the eosinophil adhesion, but the co-incubation of L-NAME with eotaxin or RANTES did not further affect the increased adhesion seen with chemokines alone. In addition, L-NAME alone (but not D-NAME) caused a significant cell degranulation, but it did not affect the CC-chemokine-induced cell degranulation. Incubation of eosinophils with eotaxin or RANTES, in absence or presence of L-NAME, did not affect the expression of VLA-4 and Mac-1 on eosinophil surface. Eotaxin and RANTES (100 ng/ml each) also failed to elevate the cyclic GMP levels above baseline in human eosinophils.
Conclusion:
Eotaxin and RANTES increase the eosinophil adhesion to fibronectin-coated plates and promote cell degranulation by NO-independent mechanisms. The failure of CC-chemokines to affect VLA-4 and Mac-1 expression suggests that changes in integrin function (avidity or affinity) are rather involved in the enhanced adhesion.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/13</link>
			
			 	<dc:creator>Let&#237;cia Lintomen, Gilberto Franchi, Alexandre Nowill, Antonio Condino-Neto, Gilberto de Nucci, Angelina Zanesco and Edson Antunes</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:13</dc:source>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/12">
            
            <title>Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity</title>
			<description>Background:
Neutrophil products like matrix metalloproteinases (MMP), involved in bacterial defence mechanisms, possibly induce lung damage and are elevated locally during hospital- acquired pneumonia (HAP). In HAP the virulence of bacterial species is known to be different. The aim of this study was to investigate the influence of high-risk bacteria like S. aureus and pseudomonas species on pulmonary MMPconcentration in human pneumonia.
Methods:
In 37 patients with HAP and 16 controls, MMP-8, MMP-9 and tissue inhibitors of MMP (TIMP) were analysed by ELISA and MMP-9 activity using zymography in bronchoalveolar lavage (BAL).
Results:
MMP-9 activity in mini-BAL was increased in HAP patients versus controls (149 &#177; 41 vs. 34 &#177; 11, p &lt; 0.0001). In subgroup analysis, the highest MMP concentrations and activity were seen in patients with high-risk bacteria: patients with high-risk bacteria MMP-9 1168 &#177; 266 vs. patients with low-risk bacteria 224 &#177; 119 ng/ml p &lt; 0.0001, MMP-9 gelatinolytic activity 325 &#177; 106 vs. 67 &#177; 14, p &lt; 0.0002. In addition, the MMP-8 and MMP-9 concentration was associated with the state of ventilation and systemic inflammatory marker like CRP.
Conclusion:
Pulmonary MMP concentrations and MMP activity are elevated in patients with HAP. This effect is most pronounced in patients with high-risk bacteria. Artificial ventilation may play an additional role in protease activation.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/12</link>
			
			 	<dc:creator>Bernhard Schaaf, Cornelia Liebau, Volkhard Kurowski, Daniel Droemann and Klaus Dalhoff</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:12</dc:source>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-12</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/11">
            
            <title>The information and support needs of patients discharged after a short hospital stay for treatment of low-risk Community Acquired Pneumonia: implications for treatment without admission</title>
			<description>Background:
There is increasing evidence that patients with low-risk community acquired pneumonia (CAP) can be effectively treated as outpatients. This study aimed to explore patients' experiences of having pneumonia and seeking health care; their perceptions of the information provided by health professionals; how they self managed at home; their information and support needs; and their beliefs and preferences regarding site of care.
Methods:
We conducted qualitative, semi-structured interviews with 15 patients who had a confirmed diagnosis of low-risk CAP and had received fewer than 3 days hospital care. Interviews were audio recorded and transcribed, and data were analysed thematically.
Results:
Most patients left hospital with no clear understanding of pneumonia, its treatment or follow-up and most identified additional-other specific information needs when they got home. Some were unable to independently address their activities of daily living in their first days at home.Main concerns after discharge related to the cause and implications of pneumonia, symptom trajectory and prevention of transmission. Most sought advice from their GP in their first days at home, and indicated they would have appreciated a follow-up phone call or visit to discuss their concerns.Patients' preferences for site of care varied and appeared to be influenced by beliefs about safety (fear of rapid deterioration at home or acquiring an infection in hospital), family burden, access to support, or confidence in home-care services. Those who received intravenous (IV) medication were more likely to state a preference for hospital care.
Conclusion:
Trends to support community-based treatment of CAP should be accompanied by increased attention to the information and support needs of patients who go home to self-manage. Although some information needs can be anticipated and addressed on diagnosis, specific needs often do not become apparent until patients return home, so some access to information and support in the community is likely to be necessary. Our finding that patients who received IV treatment for low-risk CAP were concerned about the relative safety of home-based care highlights the potential importance of the inferences patients make from treatment modalities, and also the need to ensure that patients' expectations and understandings are managed effectively.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/11</link>
			
			 	<dc:creator>Deborah J Baldie, Vikki A Entwistle and Peter G Davey</dc:creator>
			
			<dc:source>BMC Pulmonary Medicine 2008, 8:11</dc:source>
			<dc:date>2008-07-29</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-11</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
